by Congenital hyperinsulinism is a rare genetic disorder in which the pancreas produces excessive insulin even when blood sugar levels start falling dangerously low. The excess insulin that enters the bloodstream causes the blood sugar levels to drop, resulting in a dangerous hypoglycemic state. Due to low blood glucose levels, infants and young children with CHI may experience seizures, difficulty feeding, failure to thrive, poor muscle tone or stiffness, irritability, drowsiness or loss of consciousness. Continuous intravenous glucose infusion and oral medications such as diazoxide and glyburide are used as first-line treatment options. However, for some drug-resistant cases, surgery to remove a portion of the insulin-producing part of the pancreas may be required.
The global Congenital Hyperinsulinism Treatment Market is estimated to be valued at US$ 250.84 Bn in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the congenital hyperinsulinism treatment market is increasing research on gene therapy. Gene therapy aims to treat genetic diseases by replacing or repairing a mutated gene or introducing a healthy copy of the gene. Several research studies are ongoing to explore gene therapy approaches for CHI. For example, a Phase I/II clinical trial is evaluating the safety and efficacy of a gene therapy approach using an adeno-associated virus vector to deliver the gene coding for human glucose-6-phosphatase to pancreatic islet cells of CHI patients. If successful, gene therapy has the potential to provide long-term treatment benefits with a single intervention for certain forms of congenital hyperinsulinism. This is expected to drive the congenital hyperinsulinism treatment market during the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the congenital hyperinsulinism treatment market is low due to high R&D costs, regulatory barriers.
Bargaining power of buyers: The bargaining power of buyers is moderate as there are many established treatment options available.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as there are many raw material suppliers.
Threat of new substitutes: The threat of new substitutes is low as there are limited treatment options for congenital hyperinsulinism.
Competitive rivalry: The competitive rivalry is high among existing players due to increasing generic competition.
Key Takeaways
The Global Congenital Hyperinsulinism Treatment Market Demand is expected to witness high growth. The global Congenital Hyperinsulinism Treatment Market is estimated to be valued at US$ 250.84 Bn in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2024 to 2031.
Regional analysis shows that North America is expected to dominate the market over the forecast period owing to high awareness and developed healthcare infrastructure in the region. Europe is also expected to grow significantly in the congenital hyperinsulinism treatment market attributable to rising healthcare expenditure and presence of leading market players in countries like Germany, U.K, and France.
Key players operating in the congenital hyperinsulinism treatment market are Medtronic, Ace-medical, VOGT MEDICAL, BD (Becton, Dickinson and Company), Smiths Medical, Inc., Samtronic., CODAN ARGUS AG, B. Braun SE, Medical Components, Inc., Fresenius SE & Co. KGaA, Baxter, EuroLife Healthcare Pvt. Ltd, and Micrel Medical Devices.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
